Navigation Links
Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig
Date:9/22/2008

WAYNE, Penn., Sept. 22 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that at this time Encorium and Prologue have mutually agreed to postpone negotiations regarding Encorium's planned acquisition of Prologue. Instead, the management teams of the two companies have decided to form a strategic partnership while leaving open the possibility of restarting negotiations relating to a merger of the two entities at a later date.

In conjunction with the postponement of negotiations with Prologue, Encorium's management and Board has initiated a strategic reorganization designed to cut costs and preserve capital. As an initial action to achieve profitability, Encorium is announcing an immediate reduction of its staff in the United States by approximately 18%. In addition to this and other immediate actions to improve profitability in its U.S. and European operations, Encorium will focus its management energies on intracompany sales growth as well. The Company also announced that it has engaged Mufson Howe Hunter & Company LLC to investigate possible strategic alternatives to maximize shareholder value.

"While we are disappointed we could not reach a final agreement on the acquisition at this time, in light of the strong strategic and cultural fit between Encorium and Prologue and their respective management teams, we believe that the formation of a strategic partnership will enable us to realize many of the potential benefits that a transaction could have created," stated Kai Lindevall, Executive Chairman of the Board of Enc
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Encorium Group Signs $6.2 Million of New Contracts Mainly for Vaccines Clinical Trials
2. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) Needle
3. Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis
4. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
5. Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to Topamax(R)
6. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
7. Sunshine Heart Announces IDE Approval To Begin C-Pulse U.S. Clinical Feasibility Trial
8. Cerimon Pharmaceuticals Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain
9. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
10. Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
11. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 2015  Delcath Systems, Inc. (NASDAQ: DCTH ... focused on oncology with an emphasis on the ... the reporting of data from a single -center ... with the Delcath Hepatic Delivery System (Melphalan/HDS) and ... Society of Surgical Oncology (SSO) Annual Meeting 2015.  ...
(Date:3/27/2015)... , March 27, 2015  WebMD Health ... source of health information, today announced an ... National Action Plan for Combating Antibiotic-Resistant ... emphasized the urgency and importance of addressing ... and global health.    The WebMD ...
(Date:3/26/2015)... - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), ... therapies for cardiovascular disease and overall health, announced that ... of the Corporation (the "Common Shares"). The Common Shares ... 5 th , 2014 to March 4 th , ... on or before April 1, 2015. Interest on the ...
Breaking Medicine Technology:Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2
(Date:3/27/2015)... When struck with the aftermath of ... where to begin. The latest eBook released by ... offers accident victims a clear and concise process for ... their personal injury claim is seen through to successful ... actions that should be taken immediately following the trucking ...
(Date:3/27/2015)... 2015 Trail mix is the perfect, healthy ... weekend hikes and during the game! It’s portable, lightweight and ... proud to introduce a new line of specialty trail mixes ... and flavorful selections packed with nutritious, 100% all natural ingredients. ... grains that add protein and fiber to your diet and ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Approximately ... for Healthy Kids Coalition Lobby Day to lobby ... Health Improvement Program (SHIP). Everlast Climbing was ... PE Bill SF343/HF498 which would strengthen physical education ... student assessments and other measures to strengthen physical ...
(Date:3/27/2015)... 27, 2015 Since September 2014, the country ... comeback tour after having been in retirement for a period ... the performer to return to touring, and concert events have ... Omaha will likely sell out for the two shows recently ... to view the inventory of discounted Garth Brooks tickets ...
(Date:3/27/2015)... Canadian Cannabis Clinics ( http://www.cannabisclinics.ca ... utilization of medical cannabis as a treatment for ... and clinics dedicated to providing access to safe ... for patients searching for medical marijuana treatment in ... their sub domain for Canada. , With ...
Breaking Medicine News(10 mins):Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2Health News:Aurora Product, Inc. Introduces New Line of Specialty Trail Mixes 2Health News:Everlast Climbing Advocates to Strengthen Physical Education in Minnesota Schools 2Health News:Garth Brooks Tickets for Omaha: BuyCheapTicketsToEvents.com Draws Customers by Discounting Prices on 2015 Tickets for Garth Brooks’ Tour Stops at CenturyLink Center 2Health News:Canadian Cannabis Clinics (CCC) to Join the Canada.MarijuanaDoctors.com Network 2
... for regulating the immune system, an international team of ... that have the potential to treat diseases involving inflammation, ... The team started by creating a three-dimensional map of ... on the surface of human cells and plays a ...
... HealthDay Reporter , MONDAY, May 14 (HealthDay News) -- ... may help relieve shortness of breath during activity, Japanese ... that makes it hard to breathe; it is commonly ... "The effects of acupuncture are large," said Dr. George ...
... , SUNDAY, May 13 (HealthDay News) -- A new type ... people who have lost their vision due to degenerative eye ... research with rats. The system uses tiny solar panel-like ... a specially designed pair of goggles equipped with a miniature ...
... study has found that, contrary to current thinking, taking beta ... person,s risk of developing colorectal cancer. Published early online in ... Society, the study also revealed that even long-term use or ... risk. In recent years, researchers have thought that beta ...
... May 10 (HealthDay News) -- An advisory panel to the ... the weight-loss medication lorcaserin, even though concerns remain about cardiovascular ... nod to the drug, lorcaserin would become the first new ... FDA is not bound to follow the advice of its ...
... cause of death among children under 5, according to a ... School of Public Health. They examined the distribution of child ... percent were attributable to infectious causes and 40 percent occurred ... of the Lancet , suggest a decline in the ...
Cached Medicine News:Health News:Novel drug candidates offer new route to controlling inflammation 2Health News:Novel drug candidates offer new route to controlling inflammation 3Health News:Acupuncture May Help Ease Symptoms of COPD 2Health News:Acupuncture May Help Ease Symptoms of COPD 3Health News:In Rat Study, Eye Device Shows Promise for Restoring Sight 2Health News:Blood pressure drugs don't protect against colorectal cancer 2Health News:FDA Panel Gives Blessing to New Weight-Loss Drug 2Health News:Pneumonia and preterm birth complications are the leading causes of childhood death 2
Inquire...
Blood grouping tubes are available in two formulations, ACD-A, ACD-B or with a CPDA solution. Blood grouping tubes are for blood grouping determinations and also for cell preservation....
Blood grouping tubes are available in two formulations, ACD-A, ACD-B or with a CPDA solution. Blood grouping tubes are for blood grouping determinations and also for cell preservation....
... BD Vacutainer® SST™ ... and a polymer gel ... are used for serum ... also provide an efficient ...
Medicine Products: